Oakland, CA, United States of America

Brian Kane

This inventor holds 18 USPTO granted patents and 11 published patent applications, plus 3 CIPO patents and 9 EPO patents, primarily in Cardiovascular Drug Discovery. Top assignees: Portola Pharmaceuticals, Inc., Myokardia, Inc.. Active years: 2011-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Brian Kane. Retrieved from https://idiyas.com/inventor/brian-kane

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 7.8

ph-index = 5

Forward Citations = 81(Granted Patents)


Location History:

  • Pleasant Hill, CA (US) (2011 - 2012)
  • Oakland, CA (US) (2013 - 2018)
  • San Mateo, CA (US) (2021 - 2024)

Company Filing History:


Years Active: 2011-2025

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Pyrimidinedione Compounds
Cardiac Diseases
Syk Modulators
JAK Kinase Inhibitors
Benzamides
Nicotinamides
Pyrazine Kinase Inhibitors
Bicyclic Compounds
Triazine Compounds
Cycloalkyl-Substituted
Protein Kinase Inhibitors
Therapeutic Agents
18 patents (USPTO):Explore Patents

Title: Brian Kane: Innovator in Cardiac Health

Introduction

Brian Kane is an accomplished inventor based in Oakland, California, with a remarkable portfolio comprising 17 patents. His innovative contributions focus primarily on novel compounds that address serious cardiac conditions, demonstrating his dedication to advancing medical science and improving patient outcomes.

Latest Patents

Among his latest inventions are pyrimidinedione compounds, which include novel pyrimidine dione compounds and pharmaceutically acceptable salts. These compounds are designed for the treatment of hypertrophic cardiomyopathy (HCM) and other related conditions such as left ventricular hypertrophy and diastolic dysfunction. The synthesis and characterization methods, alongside treatment methodologies, are thoroughly detailed within these patents.

Additionally, Kane has developed substituted 5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4-diones. These compounds are also tailored for treating HCM and its associated cardiac ailments. The inventive work not only outlines the synthesis and characterization of these compounds but also provides methods to effectively address a range of heart diseases.

Career Highlights

Kane has established a strong career in the pharmaceutical industry, having worked for reputable organizations such as Portola Pharmaceuticals, Inc. and Myokardia, Inc. His positions at these companies have allowed him to lead impactful research and development initiatives, contributing significantly to the field of cardiac health.

Collaborations

Throughout his career, Kane has collaborated with notable colleagues, including Yonghong Song and Zhaozhong Jon Jia. These partnerships have been instrumental in facilitating the development of innovative therapies that hold promise for better management of cardiac conditions.

Conclusion

Brian Kane's work continues to make significant strides in the realm of cardiology, with his numerous patents reflecting his commitment to medical innovation. His novel compounds not only address pressing health challenges but also pave the way for future research and treatment options in the field of heart disease.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…